OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
NEW YORK, June 26, 2017 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of Roche Holding AG ("Roche Holding") (OTC:RHHBY) between March 2, 2017 and June 5, 2017. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the District of New Jersey. To get more information go to:
http://www.zlk.com/pslra-sb/roche-holding-ag?wire=3
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that throughout the class period Defendants issued materially false and/or misleading statements and/or failed to disclose that: (1) the combination of Perjeta and Herceptin is only marginally more effective than Herceptin alone in preventing breast cancer; and (2) as a result, Defendants' statements about Roche Holding AG's business, operations and prospects were materially false and misleading and/or lacked a reasonable bases at all relevant times.
If you suffered a loss in Roche Holding you have until August 7, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com
